Author Archives: admin
Phoenix PharmaLabs Announces New Investment Offering with Netcapital
Article courtesy of Business Wire December 21, 2020 10:00 AM Eastern Standard Time SALT LAKE CITY–(BUSINESS WIRE)–Phoenix PharmaLabs, a privately held, preclinical drug company dedicated to developing potent, non-addictive treatments for pain and opioid and cocaine addictions, announced it has launched its second offering campaign on the Netcapital platform: https://netcapital.com/companies/phoenix. Proceeds from this campaign will further […]
Event: Utah’s Coronavirus Pandemic Response
On January 7, join the three-hour event featuring topics such as company COVID responses, the pandemic’s impact on the real estate industry, innovations in life sciences, and more! Learn more and register here.
IONIQ Sciences Designated ‘Most Innovative Cancer Detection and Diagnostics Technology Firm’ by CV Magazine
12/10/2020 – IONIQ Sciences has been designated as 2020’s ‘Most Innovative Cancer Detection and Diagnostics Technology Firm’ by CV Magazine. Our goal to modernize cancer testing has taken us to exciting heights this year. We resolutely believe in our potential to introduce a ‘breakthrough’ Multi-Cancer Screen that will non-invasively detect the presence of malignancy in its earliest stages utilizing our Electrical Impedance Analytics […]
Sumitomo Dainippon Pharma Oncology Announces First Patient Dosed in the Dubermatinib Arm of The Leukemia & Lymphoma Society’s Beat AML Master Clinical Trial in Patients with Acute Myeloid Leukemia
Sumitomo Dainippon Pharma Oncology, Inc., a developer of novel cancer therapeutics, today announced the first patient has been dosed in a Phase 1b/2 study evaluating the oral investigational agent, dubermatinib (TP-0903), an AXL kinase inhibitor, in combination with decitabine, in patients 60 years or older with newly diagnosed acute myeloid leukemia (AML) who have TP53 […]
Sumitomo Dainippon Pharma Oncology Announces First Patient Dosed in Phase 2 of Cancer Study
Sumitomo Dainippon Pharma Oncology, Inc., a developer of novel cancer therapeutics, today announced the first patient has been dosed in the Phase 2 expansion portion of the study evaluating DSP-7888, an investigational immunotherapeutic cancer vaccine that targets Wilms Tumor 1 (WT1), in combination with checkpoint inhibitor pembrolizumab, in patients with platinum-resistant ovarian cancer (PROC). The […]
BIO-Europe Spring 2021
The fifteenth annual BIO-Europe Spring® premier springtime partnering conference will be held March 22-25 in a fully digital format. It will include on-demand early access to the company pitches, program sessions, and sponsor and showcase company content up to five weeks prior to the live event for the best possible networking and meeting decisions once […]
BIO Asia International Conference
The BIO Asia International Conference in Tokyo brings together the global biotechnology and pharmaceutical industry to explore licensing collaborations and investor engagement in the current Asia-Pacific business and policy environments. Gain insights into the changes, challenges, and opportunities key opinion and policy leaders foresee for the Japanese biotech market and throughout the region. Companies with […]
2021 BIO CEO & Investor Digital Conference
For more than 20 years, the BIO CEO & Investor Conference has fueled biotech industry networking with premier investor and banking communities, focused on established and emerging publicly traded and select private biotech companies. The virtual 2021 event, taking place February 16-18, will showcase the Biotechnology Innovation Organization’s (BIO) perspective on the new U.S. Congressional […]
BIO Partnering at JPM
Maximize Your Time During JPM Week with BIO One-on-One Partnering™ BIO One-on-One Partnering is your virtual partnering and business development companion, with integrated video conferencing and more biotechnology-specific search filters & therapeutic categories than any other major platform to help you target potential partners faster than ever. Learn more about BIO One-on-One Partnering → Participating in BIO […]
BioUtah Letter on Prioritizing Life Sciences Workers for Vaccine Distribution
December 3, 2020 Mr. Rich Lakin, MSPH, MPA Immunizations Director Utah Department of Health Bureau of Epidemiology PO Box 142102 Salt Lake City, UT 84114-2102 Dear Director Lakin: As a state plan for the allocation of COVID-19 vaccinations is formulated, BioUtah urges you to include employees of Utah’s life sciences companies among priority recipients of […]
BIO to Issue Legal Challenge to Most Favored Nation Rule
A letter written by BIO’s president and CEO Michelle McMurry-Heath dated December 4, 2020. Dear BIO Members, Today BIO, together with California Life Sciences Association (CLSA) and BIOCOM California, will announce our plan to challenge the Department of Health and Human Services’ (HHS) attempt, during the final days of the Trump Administration, to implement for […]
